Skip to main content
OpenTrials
Completed

NCT Number: NCT02930681

Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects

Glucosanol had previously been proven to be effective in aiding weight loss and weight loss maintenance. Studies have also shown that Glucosanol (also known as Phaseolamin), was effective in aiding weight loss and also has evidence on reducing post-prandial glucose levels. This study is to enrich the existing evidence on dose-dependent post-prandial glucose effects of Glucosanol

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

analyze & realize GmbH

Berlin, State of Berlin, D-13467, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caucasian males and females, 18 to 65 years old
  • Body mass index (BMI) 25.0-29.9 kg/m2
  • Generally in good health
  • Normal fasting blood glucose (FBG) 3.9- <5.6 mmol/L (70- <100 mg/dL) and glycated hemoglobin HbA1c of 4- <5.7 %
  • Readiness to adhere to consumption of test meals and defined restrictions prior to test meals (refer to section 11.8 for details)
  • Readiness to adhere to habitual lifestyle during the study, in particular to:
  • maintain the same level of physical activity during the study, including non-strenuous transportation to the study visits
  • if smoking, regular smoking at the same level as prior
  • to the study and no smoking on days of test meals
  • prior and during the visit
  • Stable body weight in the last 3 months prior to V1 (≤5% self-reported change)
  • Stable concomitant medications (if any) for at least last 3 months prior to V1
  • Women of child-bearing potential only:
  • negative pregnancy testing (ß-HCG in urine at V1)
  • commitment to use reliable contraception methods

Exclusion criteria

  • Known sensitivity to any ingredients / excipients of the IP
  • Known food allergy (e.g. to cow's milk, eggs, wheat, crustacean, nuts etc.)
  • Clinically relevant excursions of safety parameters
  • Digestion/absorption disorders in gastrointestinal (GI) tract (e.g. inflammatory bowel disease)
  • Uncontrolled hypertension >140/90 mmHg at V1
  • Uncontrolled thyroid disorder at V1
  • Any serious condition or disease that renders subjects ineligible
  • Change in daily dose of any treatment and/or use of supplements with a possible impact on glycemic control in the last 3 months prior to V1 and throughout the study (refer to section 10 for details)
  • Use of any anti-diabetic treatment or use of treatment and/or supplementation, for reduction of blood glucose levels within the last 4 weeks before V1 and throughout the study
  • Use of medications or dietary supplements that may influence body weight ≤4 weeks and gastrointestinal functions ≤2 weeks prior to V1 and during the study
  • Antibiotic and cortisone therapy ≤2 weeks prior to V1 and during the study
  • Vegetarians and subjects with self-reported diet high in fat or protein
  • Strenuous exercise within one day prior to each blood glucose sampling (including V1)
  • History of bariatric surgery, small bowel resection or extensive bowel resection
  • Recent blood donation within ≤1 month prior to study
  • Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits) and any alcohol consumption within 24 h before blood glucose sampling
  • Inability to comply with study procedures
  • Pregnancy or nursing
  • Participation in another study during the last 30 days of the screening visit (V1)
  • Any other reason deemed suitable for exclusion, per investigator's judgment

Treatment and study plan

Glucosanol 500mg

Dietary Supplement

Placebo

Dietary Supplement

Primary outcomes

  1. Change in total PPG between verum 1000mg and 2000mg study arms vs the placebo study arm

    Time frame: 120 mins

    Change defined as incremental AUC0 - AUC120min in mmol/(L*min)

Sponsors and collaborators

Lead sponsor

InQpharm Group

Industry

Registry information

Official study title

Double-blind, Randomised, Placebo-controlled, 3-way Cross-over Study to Evaluate the Benefit of Two Glucosanol™ Dosages to Reduce Post-prandial Glucose Levels in Overweight Subjects

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Oct 12, 2016
Registry last updated
Feb 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.